Cargando…

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints

Nonalcoholic fatty liver disease (NAFLD) is common in children and may progress to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and even cirrhosis in childhood or early adulthood, indicating the need for pharmacologic treatment in this age group. Multiple trials are evaluating different t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alkhouri, Naim, Kohli, Rohit, Feldstein, Ariel E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887671/ https://www.ncbi.nlm.nih.gov/pubmed/31832567 http://dx.doi.org/10.1002/hep4.1449

Ejemplares similares

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
por: Shi, Yi-wen, et al.
Publicado: (2023)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic
por: Filozof, Claudia, et al.
Publicado: (2017)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials
por: Thorlund, Kristian, et al.
Publicado: (2023)

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
por: Younossi, Zobair M., et al.
Publicado: (2021)

Hepatic natural killer T‐cell and CD8+ T‐cell signatures in mice with nonalcoholic steatohepatitis
por: Bhattacharjee, Jashdeep, et al.
Publicado: (2017)

Rebaudioside affords hepatoprotection ameliorating sugar sweetened beverage- induced nonalcoholic steatohepatitis
por: Xi, Dong, et al.
Publicado: (2020)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
por: Povero, Davide, et al.
Publicado: (2016)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

Metformin in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Kazemi, Rozana, et al.
Publicado: (2012)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
por: Sinha, Rohit A., et al.
Publicado: (2020)

The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Nonalcoholic Fatty Liver Disease
por: Alkhouri, Naim, et al.
Publicado: (2014)

Recurrence of Disease Following Liver Transplantation: Nonalcoholic Steatohepatitis vs Hepatitis C Virus Infection
por: Hanouneh, I. A., et al.
Publicado: (2011)

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
por: Alkhouri, Naim, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
por: Tomah, Shaheen, et al.
Publicado: (2020)

MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
por: Loomba, Rohit
Publicado: (2021)

Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19
por: McCaw, Zachary R., et al.
Publicado: (2020)

Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials
por: He, Lingling, et al.
Publicado: (2016)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis
por: Seen, Tasur Kumar, et al.
Publicado: (2021)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis
por: Davison, Beth A, et al.
Publicado: (2021)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eelcd5j4ejt43vsa83umrf0vmp